Oncorine, the first oncolytic virus approved for clinical use, achieves selective lysis of tumor cells by deleting the coding region of the virulence protein that inactivates p53 in normal cells, resulting in the virus replicating only in malignant cells with abnormal p53 function [82]. This evidence concerns the gene TP53 and neoplasm.